Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00186888 · ClinicalTrials.gov registry record · Phase 3

Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma

A Phase 3 study, sponsored by St. Jude Children's Research Hospital.

Completed
Registry status
Phase 3
Development phase
107
Enrollment target

NCT00186888: Completed Phase 3 study, sponsored by St. Jude Children's Research Hospital.

NCT00186888 is a Phase 3 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 107 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00186888, a Phase 3 study, has completed, sponsored by St. Jude Children's Research Hospital.

COMPLETED
Registry status
Phase 3
Development phase
107 participants
Enrollment target

Study Summary

Retinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain. When only one eye is affected, this is known as unilateral retinoblastoma and when both eyes are affected, it is called bilateral retinoblastoma. Treatment for retinoblastoma is individualized for each patient and is based on the form and the stage of the disease (inside the eye or has moved outside). The main goal is always to cure the cancer, and save the life of the child. Treatments are also designed with the hope of saving the vision, while completely destroying the tumor. Therapies may involve surgery, chemotherapy, radiation, and other treatments called focal treatments. Focal treatments may be laser therapy, freezing, or heat treatments meant to shrink and kill the tumor. In this study, researchers want to investigate how different participants respond to different therapies that are individualized specifically for them. Participants will be divided into three main groups, depending on whether the disease is unilateral or bilateral, and the stage of the disease. One of the main objectives of the study is to investigate how advanced tumors in children with bilateral disease respond to a new combination of chemotherapy with topotecan and vincristine, with G-CSF support. In order to improve results, some children with very advanced disease may receive carboplatin chemotherapy given around the eye at the same time that they receive topotecan by vein. Also, because children with retinoblastoma are diagnosed so early in life and the vision may be significantly impaired, this study will investigate how children develop and how the brain adjusts and compensates for the visual deficits. Finally, this study also investigates the biology of retinoblastoma, in order to understand better how this cancer develops.

Primary Outcome

The primary outcome is to estimate the proportion of stratum B patients responding to 2 courses of window therapy consisting of vincristine and topotecan. Complete Response is the complete regression of all apparent tumor masses in the funduscopic examination and by MRI and ultrasound (US). Partial Response is defined as greater than 50% (but less than 100%) reduction of the tumor masses in the funduscopic examination and by US and MRI, without the appearance of any new lesions. The response mus

Interventions

  • RADIATION External Beam Radiation
  • PROCEDURE Enucleation
  • DRUG Vincristine, Carboplatin
  • PROCEDURE Focal Therapies
  • DRUG Vincristine and Topotecan

Trial Details

FieldValue
Enrollment Target 107 participants
Start Date 2005-04-07
Est. Completion 2024-11-12
Phase Phase 3

What the finished NCT00186888 record still lists

NCT00186888 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower).

The record links to 0 conditions, and to 5 interventions - of which External Beam Radiation is the first listed.

NCT00186888 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00186888 about?

NCT00186888 is a clinical study titled "Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma". Retinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain. When only one eye is affected, this is known as unilateral retinoblastoma and wh...

What is the current status of trial NCT00186888?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 107 participants. The study started on 2005-04-07. Estimated completion is 2024-11-12.

What interventions are being tested in trial NCT00186888?

The interventions under investigation include: External Beam Radiation (RADIATION), Enucleation (PROCEDURE), Vincristine, Carboplatin (DRUG), Focal Therapies (PROCEDURE), Vincristine and Topotecan (DRUG).

Who is sponsoring clinical trial NCT00186888?

This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00186888's enrollment target sits among peer trials

107 1666th of 2000 higher than 335 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05491668 · 107 participants

    Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI

  • NCT06041594 · 107 participants · NA

    Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)

  • NCT06081426 · 107 participants · NA

    Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)

  • NCT06527599 · 107 participants · NA

    Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00186888, the US trial registry maintained by the National Library of Medicine. NCT00186888 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.